CG Oncology picks up $47m Series D

CG Oncology, Inc, a developer of novel oncolytic immunotherapies, has raised $47 million in Series D funding.

CG Oncology, Inc, a developer of novel oncolytic immunotherapies, has raised $47 million in Series D funding. The lead investor was Kissei Pharmaceutical Co. Ltd.

Source: Press Release